A bodyweight-dependent allometric exponent model for scaling clearance of clotting factor VIII and IX from infants to adults.

about

A bodyweight-dependent allometric exponent model for scaling clearance of clotting factor VIII and IX from infants to adults.

Item

http://www.wikidata.org/entity/Q45862027

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

A bodyweight-dependent allomet ...... and IX from infants to adults.

@en

A bodyweight-dependent allomet ...... and IX from infants to adults.

@nl

type

Item

label

A bodyweight-dependent allomet ...... and IX from infants to adults.

@en

A bodyweight-dependent allomet ...... and IX from infants to adults.

@nl

prefLabel

A bodyweight-dependent allomet ...... and IX from infants to adults.

@en

A bodyweight-dependent allomet ...... and IX from infants to adults.

@nl

P1476

A bodyweight-dependent allomet ...... and IX from infants to adults.

@en

P2093

I Mahmood

http://www.w3.org/2001/XMLSchema#string

M A Tegenge

http://www.w3.org/2001/XMLSchema#string

P2860

A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.

Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics.

Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Prediction of Drug Clearance in Premature and Mature Neonates, Infants, and Children ≤2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric Models.

Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model.

Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.

Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.

P304

e570-e573

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13116

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27868371

http://www.w3.org/2001/XMLSchema#string